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It is well established that amyloid fibril solubility is protein specific, but how solubility depends
on the interactions between the fibril building blocks is not clear. Here we use a simple protein
model and perform Monte Carlo simulations to directly measure the solubility of amyloid fibrils as
a function of the interaction between the fibril building blocks. Our simulations confirms that the
fibril solubility depends on the fibril thickness and that the relationship between the interactions
and the solubility can be described by a simple analytical formula. The results presented in this
study reveal general rules how side-chain side-chain interactions, backbone hydrogen bonding and
temperature affect amyloid fibril solubility, which might prove a powerful tool to design protein
fibrils with desired solubility and aggregation properties in general.
INTRODUCTION
The maintenance of proteins in their soluble state is
crucial to protein homeostasis in living organisms because
small changes in their concentration can lead to amyloid-
related diseases1,2. At a given temperature, the solubility
Ce (also known as the “critical concentration”
3–6) is the
concentration of monomers C at which the solution is
saturated, for then the fibrils in solution cannot lengthen
or shorten. Its importance for example in protein home-
ostasis arises, because the fibril solubility determines the
concentration at which the fibrils can form, as well as
the fibrilallion kinetics6,7 as it is a central parameter in
existing nucleation theories (e.g. refs.4,6,8–11).
Experimental measurements of fibrils solubilities are
intrinsically difficult, because they can be very low12–18
(typically 0.1-100 µM), and are beyond the detection
limit of commonly used techniques for small oligomers
and fibrils19. Experiments are usually made at high
concentrations where fibrils form spontaneously, or in
the presence of preformed fibrils, and fibril solubilities
can be determined by the ratio of the on and off rates of
fibril elongation13,19. These experiments show that fibril
solubilities can vary strongly with point mutations of the
amino acid sequence20–22, and the fibril structure23,24.
Theoretically, a statistical mechanical description of
the fibril solubility can be obtained in the case of linear
aggregation in terms of molecular partition functions
(e.g. refs.3,5,25,26). Also, aggregation propensities might
be predicted from protein physicochemical properties by
using knowledge-based computational approaches27–30
but they are not able to distinguish between different
fibril structures. The thermodynamic stability of amyloid
fibrils has been studied by computer simulations using
full-atomistic description of proteins31,32 but they are
restricted to fibrils composed of small peptide fragments
and are computationally too costly to be repeated under
different conditions to obtain a full phase diagram. Sim-
ulations using coarse-grained models to explore the self-
assembly of large peptide systems have been performed,
but they often determine a kinetic rather than a thermo-
dynamic phase diagram (e.g. refs.33,34), which have been
shown to be fundamentally different35. A direct calcula-
tion of the fibril solubility has been performed by Auer et
al.36,37 that revealed the existence of various metastable
fibrillar aggregates and that the fibril solubility depends
of fibril thickness. However, such simulations are also too
costly and have only been performed for one set of inter-
action parameters. Computer simulations using a lattice
model for proteins have been performed to determine the
phase diagram from the peak in the heat capacity, but
the interpretation of this in terms of fibril solubility is
not clear38. Although lattice peptide models have been
employed to investigate fibril formation and growth39–43,
they did not provide a general understanding of how
amyloid fibril solubility is determined by protein-protein
interactions.
A theoretical relationship between the interactions of
the building blocks of an aggregate and its solubility can
be provided by a combination of the well known van’t
Hoff equation and the Haas-Drenth (HD) model44,45 but
its applicability has never been verified by computer
simulations. In its integrated form, the van’t Hoff
equation is given by
Ce = Cre
−λ , (1)
where Cr is a reference concentration and λ = L/kBT
is the dimensionless latent heat of peptide aggregation
into fibrillar aggregates The corresponding latent heat
L can be estimated theoretically by the HD model46 for
protein crystals, and λ is given by half the binding energy
of peptides in the aggregates.
PEPTIDE MODEL
To test this, we consider a peptide model that was
recently used to explore the formation of amyloid fibril
networks47. In this model, all peptides are considered
in their aggregation-prone state and are represented
by hexagons on a two-dimensional (2D) lattice with
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2FIG. 1: Illustration of an amyloid fibril composed of three
β-sheets. The fibril building blocks (i.e. the peptides) are
represented by hexagons on a triangular lattice. The four
red sides of the hexagons model the hydrophobicity-mediated
side-chain side-chain interactions between peptides, while
the black sides model directional hydrogen bonds between
peptides.
triangular symmetry, Figure 1. Each hexagon has two
opposing strong bonding sides (shown in black) and
four weaker bonding sides (shown in red), so that they
can self-assemble into a highly ordered cross-β structure
characteristic of amyloid fibrils48,49. Here the strong
bonding sides correspond to hydrogen bonding which
drives the formation of β-sheets and the weaker bonding
sides correspond to hydrophobicity-mediated side-chain
side-chain interactions that drive the fibril thickening.
The corresponding dimensionless surface energies for
the strong hydrogen and weak hydrophobicity-mediated
bonds can be written as
ψ = aσ/kBT = E/2kBT (2)
and
ψh = ahσh/kBT = Eh/2kBT , (3)
respectively. Here σ and σh are the corresponding specific
surface energies, and a and ah are the corresponding
surface areas of the peptide faces. The second equality
results from an approximation between the surface ener-
gies and the binding energies E and Eh between peptides.
The energy E corresponds to the formation of directional
backbone hydrogen bonds, whereas Eh is the energy due
to the formation of weaker bonds modeling side-chain
hydrophobic interactions between peptides. The fibril
solubility in the combined van’t Hoff and HD model is
then given by
Ce = Cre
−2ψ−4ψh , (4)
where we used that the dimensionless latent heat is given
by λ = 2ψ + 4ψh.
FIG. 2: Concentration ranges showing the fibril solubility Ce,
the metanucleation border C1β , and intermediary concentra-
tions Ciβ for i ≥ 2.
An important feature characteristic of amyloid fib-
rils is that their solubility depends on the fibril thick-
ness11,36,37,40. It has been shown that the solubility
of fibrils composed of iβ-sheet layers is given by10(i =
1, 2, 3, . . . )
Ciβ = Cee
4ψh/i . (5)
Substitution of the fibril solubility Ce given by Eq. 4 into
Eq. 5 yields (i = 1, 2, 3, . . . )
Ciβ = Cre
−2ψ−4ψh(1−1/i) . (6)
The analytical expressions given by Eqs. 4 and 6 define
the concentration range between the fibril solubility
Ce and the threshold concentration C1β at the nucle-
ation/metanucleation border (termed also “supercritical
concentration”4,6) in which fibrils nucleate10,11. As
illustrated in Figure 2, no fibrils can nucleate when the
peptide concentration C < Ce, whereas for C > C1β
the fibril nucleus is a single peptide and fibrils form
in the absence of any nucleation barrier4,10,11,45,50,51.
Importantly, for intermediate concentrations, Ce < C <
C1β , fibril nucleation and elongation depends on their
thickness41. Despite the fundamental importance of
those expressions, they have not yet been verified by
neither simulations nor experiments.
SIMULATION DETAILS
To do this we perform Monte Carlo (MC) simulations
in which we determine the equilibrium concentration
at which a fibril of a fixed thickness neither grows
nor shrinks. The simulations are performed on a 2D
triangular lattice with 5122 sites. At the beginning of
the simulation one single fibril of fixed thickness i is put
in the center of the simulation box and peptide monomers
3FIG. 3: Solubility measurements for a 1β-sheet fibril showing
that, through random attachment and detachment events, the
number concentration of peptides in solution approaches the
equilibrium concentration C1β instead of the solubility Ce.
The blue circle and red squares data were obtained from fibril
elogantion and fibril schrinkage simulations, respectively. The
horizontal dashed and dash-dotted lines are theoretical values
predicted, respectively, by Eqs. 6 and 4 considering ψ = 3 and
ψh = 0.25.
are randomly placed on the remaining lattice sites (see
Figure 1 for a snapshot). In the MC simulations we only
perform diffusion-like and rotational moves as described
in previous simulations39,47. Depending on the peptide
concentration the fibril will either elongate or shrink until
the equilibrium concentration is reached, as illustrated in
Figure 3. We emphasize that during the simulation the
fibril can only lengthen and is not allowed to thicken.
Typically in each simulation we perform 107 MC steps
and each solubility measurement is an average over four
independent simulations. In the following we present our
simulation results for the fibril solubility as a function
of the hydrophobicity parameter ψh, hydrogen bonding
parameter ψ, and temperature to verify the applicability
of Eqs. 4 and 6.
RESULTS AND DISCUSSIONS
Weak Hydrophobic Effect. The presence of
hydrophobicity-mediated bonds has been shown to
be an important factor in the formation of fibrillar
aggregates. Fibril structure and point mutations change
the interactions between side-chains of the peptides in
the fibril and can alter their aggregation propensity52.
In Figure 4a we present results of the ψh dependence
of Ciβ at fixed ψ. As can be seen from the figure,
Ciβ decreases with increasing ψh for all fibrils with
a thickness larger than one, and this effect becomes
stronger with increasing fibril thickness. The values
of Ciβ are given in units of peptides per lattice site.
Even though our results have been obtained in 2D, an
estimate for the fibril solubilities in 3D can be obtained
by scaling them as C
3/2
iβ . Such scaling implicitly
assumes that the interactions of the peptide in the third
dimension, and thereby to the latent heat, are negligible.
Assuming that the area of the lattice sites is 1 nm2, the
number concentrations in Figure 4a yields threshold
concentrations C1β in 3D around 1 mM and solubilities
Ce in 3D equal to 238 µM for ψh = 0.25 and 0.1 µM for
ψh = 1.5. Figure 4b shows the same data in a ln(Ciβ)-
vs-ψh plot. A fit of these data points to Eq. 6 with
fixed i illustrates the predicted linear dependence with
slope −4(1− 1/i). Furthermore, a plot of ln(Ciβ)-vs-1/i
(Figure 4c) can be used to fit Eq. 6, which provides
estimates for the solubility Ce in the limit of i→∞ and
the reference concentration Cr. There is good agreement
between the estimates for Ce obtained by this scaling
analysis and the direct measurements (Figure 4b), and
Cr is independent of ψh (Figure 4d). We note that the
value Cr ≈ 3 (in units of peptides per lattice site) is
related to the number of states that peptides can assume
in our lattice model (Figure 1). The reason for this is
that only one of the three possible orientations can lead
to a successful monomer attachment to the fibril, so that
there will be 3 times more monomers in solution than
would be if all of them were in the same alignment of
the peptides in the fibril. Furthermore, the fact that Cr
is independent of ψh is important for theoretical studies
to predict changes in the solubility as it can be assumed
constant (see e.g. ref.45). Thus, the main effect of
decreasing the hydrophobicity-mediated interactions ψh
is that it increases the solubilities Ce and Ciβ for i > 1,
but does not alter the metanucleation border C1β . This
rationalizes the experimental observations that amino
acid substitutions that decrease the hydrophobicity-
mediated interaction between the fibril building blocks
decrease its aggregation propensity20,21,52–54.
Hydrogen Bonding Effect. The lengthening of amyloid
fibrils is driven by the formation of backbone hydrogen
bonds in the direction of the fibril lengthening axis.
The strength of the hydrogen bonding network between
neigboring peptides in the fibril varies depending on
the amino acid sequence, because it determines the
number of hydrogen bonds that can be formed55. To
determine the effect of changes in the hydrogen bonding
interactions we vary ψ while keeping the strength of
the hydrophobicity-mediated interactions ψh fixed. Fig-
ure 5a shows that Ciβ decreases with increasing ψ. A
plot of these data as ln(Ciβ)-vs-ψ coordinates, illustrates
a linear dependence and that the slope is independent
of the fibril thickness. Indeed, a fit of Eq. 6 with fixed
i to these data points shows that the slope is equal to
−2 for all i (Figure 5b). As before, a scaling analysis
to obtain the bulk solubility Ce in the limit of i → ∞
and the reference concentration Cr can be obtained by
4FIG. 4: (a) Dependence of solubilities Ciβ on ψh: diamonds,
up triangles, right triangles, circles, left triangles - simulation
data for 1β, 2β, 3β, 4β, 5β-sheet, respectively; squares - data
obtained for a bulk fibril (i.e. i = 100); dotted lines - guide to
the eyes only. (b) monolog plot of the same data presented in
(a); dashed lines - best fit of Eq. 6; asterisks - data obtained
for i → ∞ from scaling analysis. (c) ln(Ciβ)-vs-1/i plot;
dashed lines - best fit of Eq. 6. (d) reference concentration Cr
obtained from the scaling analysis described in text; dashed
line is the Cr = 3 line. All results here were obtained for
ψ = 3 at room temperature, i.e. kBT = 2.5 kJ.mol
−1.
FIG. 5: (a) Dependence of solubilities Ciβ on ψ. Symbols
are the same as in Figure 4. Dotted lines are guides to the
eyes only. (b) monolog plot of the same data presented in (a);
dashed lines - best fit of Eq. 6; asterisks - data obtained for
i → ∞ from scaling analysis as described in main text. (c)
ln(Ciβ)-vs-1/i plot for the scaling analysis; dashed lines - best
fit of Eq. 6. (d) reference concentration Cr obtained from the
scaling analysis; dashed line - Cr = 3 line. All results here
were obtained for ψh = 0.5 and kBT = 2.5 kJ.mol
−1.
a fit of Eq. 6 to our data presented in a ln(Ciβ)-vs-
1/i plot (Figure 5c). As can be seen in Figure 5b,
there is again good agreement of the results obtained
from our scaling analysis and direct measurements of Ce.
Furthermore, also in this case the so obtained reference
concentration Cr ≈ 3 is independent of ψ (Figure 5d).
The main effect of decreasing the hydrogen bond energy
interaction ψ is that it increases the solubility Ce and
the threshold concentration C1β while keeping the ratio
C1β/Ce constant. This effect might explain experiments
using hydrogen-deuterium exchange mass spectrometry
to demonstrate that the solubilities of different Aβ1−40
polymorphs increases as hydrogen bond formation be-
tween proteins decreases23.
Temperature Dependence. Amyloid fibrils are known to
have high thermodynamic stability, and the temperatures
required for the dissociation of the fibril structure are far
greater than needed for e.g. the denaturation of native
proteins56. To test the effect of temperature on the
fibril solubility we performed simulations in which the we
fixed the binding energies and varied the temperature.
Figure 6a illustrates that Ciβ increases with increasing
kBT , and that this effect is less pronounced with the
increasing number of fibril layers i. In Figure 6b we
present the same data but in a ln(Ciβ)-vs-1/kBT plot. A
fit of Eq. 6 with fixed i to these data points using a ref-
erence concentration Cr = 3 shows a linear dependence
with a slope equal to −(E + 2Eh(1 − 1/i)) as predicted
by Eq. 6. Furthermore, presenting the same data in a
ln(Ciβ)-vs-1/i plot (Figure 6c), a fit of Eq. 5 to these
data points also provides estimates for the solubility Ce
from the intercept in the limit of i → ∞. As shown in
Figure 6b, such estimates are in good agreement with the
direct measurements of Ce for very thick fibrils (i.e. for
i = 100). In the limiting case when i → ∞, the slope
obtained for the bulk solubility line Ce corresponds to
the latent heat L = λkBT (Eq. 1), which remarkably
is equal to half of the binding energies E + 2Eh, as
predicted by the HD lattice model (see Figure 6d). The
fact that L is half the binding energy cross validates our
assumption that Cr = 3 in the linear fit of Eq. 5 to the
data presented in Figure 6c. Finally, the slopes obtained
from the fit of Eq. 5 to data in Figure 6c, in combination
with Eq. 3, provide values for the surface energy ahσh at
each temperature. As shown in Figure 6e, such values are
equal to half the values of the weak bond energy Eh/2.
Furthermore, combined with the estimate for the latent
heat λ, the values of ahσh can be used to estimate the
strong bond surface energies aσ. Figure 6f confirms that
the values of aσ are independent of kBT and equal to half
the binding energy of the strong bond E/2. Note that the
dashed lines in Figs. 6e and f are estimates obtained from
the fit of Eq. 6 to data presented in Figure 6 considering
i = 1. The main effect of increasing the temperature is
that it increases both C1β and Ce, which is in agreement
with experimental measurements of solubilities for a
short Aβ-model peptide57. In the example presented in
Figure 6, increasing the temperature from 10 oC to 60 oC
5FIG. 6: (a) Dependence of solubilities Ciβ on kBT . Symbols
are the same as in Figure 4. Dotted lines are guides to
the eyes only. (b) monolog plot of the same data presented
in (a); dashed lines - best fit of Eq. 1 assuming Cr = 3;
asterisks - data obtained for i→∞ from the scaling analysis
described in main text. (c) ln(Ciβ)-vs-1/i plot for the scaling
analysis; dashed lines - best fit of Eq. 5 with Cr = 3. (d)
Specific heat L extracted at each temperature from data in
(c) by considering Eqs. 1 and 5 assuming Cr = 3; dashed
line - estimate of L from the slope of ln(Ce)-vs-1/kBT in
(b) considering Eq. 1. Panels (e) and (f) show, respectively,
estimates for the surface energies ahσh and aσ evaluated from
the scaling presented in (a) by considering Eq. 1 and Eq. 5 at
each temperature assuming Cr = 3; dashed lines in (e) and (f)
are estimates extracted from the scaling in (b) for comparison
(see text). All results here were obtained for binding energies
E = 15 kJ.mol−1 and Eh = 2.5 kJ.mol
−1.
changes the solubilities Ce in 3D from 25 µM to 171 µM,
and the threshold concentration C1β in 3D from 0.61 mM
to 2.56 mM, respectively.
CONCLUSIONS
In summary, the main results of the analysis presented
is that we numerically verified Eqs. 4 and 6 which
provide simple relationships between the solubilities of
fibrils of various thickness and the dimensionless specific
surface energies that are given by half the dimensionless
binding energies between the peptides in the fibril (Eqs. 2
and 3). This is important, as these equations can be
used to e.g. estimate changes in the fibril solubility
upon point mutations or fibril structure. In combination
with existing nucleation theories they can also be used to
predict how such changes affect their fibrillation kinetics
(e.g. refs.44,45). To design peptides that assemble into
fibrils with desired solubility our analysis reveals some
general rules: (i) decreasing the hydrophobicity-mediated
interaction ψh will increase the solubility Ce, corrobo-
rating what was previously suggested by experimental
studies20,21,54; (ii) changes in ψh do not alter the value
of C1β , but the solubilities Ce and Ciβ for i > 1; (iii)
decreasing the hydrogen bond energy interaction ψ will
increase both the solubility line Ce and the metanucle-
ation border C1β while keeping ratio C1β/Ce constant;
(iv) higher temperatures increases both C1β and Ce.
Finally, we note that our model is limited to peptides
in an aggregate-prone state immersed in an implicity
athermal solvent; thus neither conformational changes
nor solvent effects57 are considered.
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